SCHEMBL5446261

SCHEMBL5446261

Cc1ccc(NC(=O)Nc2sc3cc(O)ccc3c2C(N)=O)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
CA2 P00918 1/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
MAPT P10636 4/20 0.45
KDM4E B2RXH2 2/20 0.45
HTT P42858 2/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
ATM Q13315 1/20 0.45
HSD17B10 Q99714 1/20 0.43
IDH1 O75874 1/20 0.43
KCNJ6 P48051 1/20 0.42
KCNJ5 P48544 1/20 0.42
KCNJ3 P48549 1/20 0.42
STING1 Q86WV6 1/20 0.42
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447596 0.85 GAA (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL17625475 0.84 MEN1 (0.52) NPC1RAB9ASMN1; SMN2CA2MEN1
SCHEMBL17625474 0.83 CA12 (0.43) NPC1RAB9ACA2MEN1KMT2A
SCHEMBL5458283 0.81 MEN1 (0.43) NPC1RAB9ACA2MEN1KMT2A
SCHEMBL5456326 0.81 MEN1 (0.43) NPC1RAB9ACA2MEN1KMT2A
SCHEMBL5451109 0.81 MEN1 (0.56) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL5455604 0.81 MAPT (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL5460392 0.81 RAB9A (0.49) NPC1RAB9ASMN1; SMN2CA2MEN1
SCHEMBL5460360 0.80 KDM4E (0.55) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL5459965 0.79 MDM2 (0.45) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 NPC1 2627/4885RAB9A 948/4885SMN1; SMN2 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.